Market revenue in 2024 | USD 34.8 million |
Market revenue in 2030 | USD 31.7 million |
Growth rate | -1.9% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 58.91% in 2024. Horizon Databook has segmented the South Africa anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
South Africa’s market is expected to witness slow growth owing to its poor healthcare infrastructure. According to a report in 2019, around 84% of citizens have no medical insurance, which accounts for 58.8 million people. They rely on the public health system, which has few doctors and substandard facilities, resulting in delayed or inadequate treatment.
However, the region has many growth opportunities due to the presence of a large patient pool, on account of growing geriatric population and government initiatives. According to South African Health Review 2019, the geriatric population is expected to increase from 46 million in 2015 to 157 million in 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into South Africa anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account